TQB3473 / Sino Biopharm - LARVOL DELTA

Preliminary Efficacy and Safety Results of TQB3473, a Novel Syk Inhibitor, in Adult Patients with Immune Thrombocytopenia (ITP) (ASH 2024) - "The efficacy of Syk inhibitors for treating ITP has been recognized by the approval of fostamatinib. TQB3473 600mg QD demonstrated a durable, clinically significant platelet responses across all subgroups with pretreated ITP. Continued randomized phase 3 study will further assess the durable clinical benefit of TQB3473 in adult pts with relapsed/refractory ITP."

Clinical • Cardiovascular • Diabetes • Dyslipidemia • Hematological Disorders • Hypertension • Hypertriglyceridemia • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura • SYK

A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults (clinicaltrials.gov) - P2 | N=320 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P2 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

TQB3473-III-01: Phase III Clinical Trial of TQB3473 Tablets in the Treatment of Primary Immune Thrombocytopenia in Adults (ChiCTR) - P3 | N=199 | Not yet recruiting | Sponsor: HenanCancerHospital; HenanCancerHospital

New P3 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia (clinicaltrials.gov) - P3 | N=199 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Sino Biopharmaceuticals launches first Phase III clinical trial of SYK inhibitor [Google translation] (Sino Biopharm Press Release) - "Recently, Sino Biopharmaceutical...subsidiary Chia Tai Tianqing launched a Phase III clinical trial of SYK inhibitor TQB3473 tablets for the treatment of primary immune thrombocytopenia (ITP) in adults. This is the first Phase III clinical trial of TQB3473....TQB3473-Ⅲ-01 is a randomized, double-blind, placebo-controlled, multicenter Phase III clinical study designed to evaluate the efficacy and safety of TQB3473 tablets versus placebo in the treatment of adult ITP. The dosing regimen is once a day for 24 consecutive weeks. The study plans to enroll 199 subjects, with 54 institutions nationwide participating."

Trial status • Immune Thrombocytopenic Purpura

A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia (clinicaltrials.gov) - P3 | N=199 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P3 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies (clinicaltrials.gov) - P1; N=57; Recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Hematological Malignancies • Oncology

A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies (clinicaltrials.gov) - P1; N=57; Not yet recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Clinical • New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology